AMD's Q1 earnings were impressive, with 36% YoY revenue growth and 57% YoY growth in the Data Center segment. Read why AMD stock is a Buy.

Carl Zeiss Meditec remains a high-quality medtech leader with strong moats in ophthalmic and microsurgery. Read why CZMWF stock is a Buy.

Technical strength is impressive, with the stock near 52-week highs. Further gains are likely moving forward as most indications remain bullish. Q1 earnings were mixed, with revenue growth hitting ...

ASE Technology is a market leader in the OSAT industry, leading the pack with 33% market share. Read why I rate ASX stock a ...

Keurig Dr Pepper is experiencing strong earnings momentum, with projected EPS growth at a 6% CAGR from 2025 to 2027. Read why ...

Altria management prioritizes buybacks and dividends over diversification, limiting long-term growth potential. See why ...

Eaton's strong growth potential is fueled by electrical and aerospace demand, secular trends, and margin expansion. Read why ...

OppFi's AI-driven, tech-enabled lending platform delivers strong growth and profitability. See why I rate OPFI stock a buy ...

Argan kicked off FY26 with nearly 23% YoY revenue growth and a sharp EPS beat. Read why AGX stock is a decent buy for the ...

Stride boasts strong financials, with a 14% revenue CAGR and a 33% adjusted operating income CAGR over the past two years.

Akebia Therapeutics' Vafseo expansion may boost future growth despite Auryxia's exclusivity loss. Read why AKBA stock is ...

CEFs can offer opportunities to invest in assets at below their current valuation. Check out two CEFs that have a long ...